We serve Chemical Name:2,2-diphenylcyclopropane-1-carboxylic acid CAS:7150-12-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,2-diphenylcyclopropane-1-carboxylic acid
CAS.NO:7150-12-1
Synonyms:(2,2-diphenylcyclopropyl)carboxylic acid;2,2-DIMETHYL-5-(3-INDOLYLMETHYL)-1,3-DIOXANE-4,6-DIONE;2,2-diphenyl-1-cyclopropanecarboxylic acid;(+-)-2,2-Diphenyl-cyclopropancarbonsaeure;2,2-Diphenyl-cyclopropanecarboxylic acid
Molecular Formula:C16H14O2
Molecular Weight:238.28100
HS Code:2916399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:403ºC at 760mmHg
Density:1.239g/cm3
Index of Refraction:1.633
PSA:37.30000
Exact Mass:238.09900
LogP:3.07720
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like (2,2-diphenylcyclopropyl)carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,2-Diphenyl-cyclopropanecarboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,2-Diphenyl-cyclopropanecarboxylic acid Use and application,2,2-DIMETHYL-5-(3-INDOLYLMETHYL)-1,3-DIOXANE-4,6-DIONE technical grade,usp/ep/jp grade.
Related News: Atom utilization is also better with biocatalysis; where two or more moieties on the same molecule have the capacity to undergo a particular reaction, biocatalytic processing guarantees that one site is consistently chosen over the other. 1-Phenylcyclopropanamine manufacturers Patients having Zynteglo treatment for beta thalassaemia also need conditioning treatment to clear out their bone marrow cells before receiving Zynteglo. Healthcare professionals should therefore explicitly inform patients receiving Zynteglo of the increased risk of blood cancers from medicines used in conditioning treatments. benzyl N-(2-amino-2-phenylethyl)carbamate suppliers For skin rash, the difference in response rates for anifrolumab versus placebo at week 52 were 13.5% SLE Disease Activity Index (SLEDAI), 15.5% British Isles Lupus Assessment Group index (BILAG) and 15.6% modified Cutaneous Lupus Erythematosus Disease Area and Severity Index (mCLASI). For arthritis, differences in response rates were 8.2% SLEDAI, 11.8% BILAG and 12.6% joint response. 4-bromo-2,3-dimethylaniline vendor & factory.
